NOV 07, 2017 8:00 AM PST

WEBINAR: The power of multiplexing and applications of the QuantiGene Plex Assay in oncology research and diagnostics

Sponsored by: Thermo Fisher Scientific
  • Head, Laboratory of Molecular Pathology, Faculty of Medicine and Surgery, University of Malta
      Professor Godfrey Grech is an Associate Professor at the University of Malta and currently responsible for the Molecular Pathology Research Laboratory and Director of Biotech Innovations, a spin-off company. The main research topic aims to identify biomarkers to classify breast cancer patients into a specific therapeutic group that shall benefit from activation of phosphatases as a main therapeutic option. Godfrey Grech published more than 25 peer-reviewed publications, presented more than 50 conference papers and published 5 book chapters including chapters in the co-edited book entitled "Preventive and Predictive Genetics: Towards Personalised Medicine" released by Springer. Professor Grech is a member of the Molecular Pathology working group of the European Society of Pathology, an active member of the European Association of Preventive, Predictive and Personalised medicine, and member of the Global Genomic Medicine Collaborative (G2MC).


    Cancer research diagnostic services in pathology laboratories worldwide have been negatively impacted by a lack of fresh-frozen tissue samples, the degradation of DNA and RNA in archival tissue, and tumor heterogeneity. To get accurate and reproducible gene expression and amplification results using archival material, a more robust and accurate test adapted to current clinical research workflows is needed.

    Thermo Fisher Scientific, the world leader in serving science, has developed a comprehensive portfolio of Invitrogen™ immunoassays based on Luminex® xMAP® (multianalyte profiling) technology, a high-throughput solution enabling simultaneous detection and quantitation of multiple proteins. This efficient technology has proven to be invaluable for the comprehensive study of biological systems.

    For the quantification of RNA in archival material, the Invitrogen™ QuantiGene™ Plex Assay is a fast and efficient multiplex solution using branched DNA (bDNA) technology on Luminex technology–based magnetic beads. Institutions, as well as professors like Godfrey Grech, have partnered with Thermo Fisher Scientific to apply this method, and have determined that it has a wide range of potential applications in the diagnosis of tumors and is adaptable to the current diagnostic research workflow.

    Professor Grech will explain the main advantages of this method, including: (1) accurate, simultaneous detection of multiple targets simultaneously, enhancing accuracy and sensitivity while minimizing use of precious patient samples, (2) exclusion of subjectivity and ambiguous results originating from image-based measurements, and (3) elimination of requirements for highly specialized facilities and human resources.

    This method has a wide range of possible applications, including tumor classification with diagnostic potential and measurement of biomarkers in liquid biopsies, enabling better patient management and disease monitoring. Quantitative measurement of biomarkers in archival material is also useful in oncology research with access to libraries of clinically annotated material—allowing for the validation of potential biomarkers and their correlation with clinical research outcomes using retrospective studies.  

    In this webinar, we will cover the following topics:

    • The benefits of multiplexing and Luminex technologies
    • The use of QuantiGene Plex Assays to accurately measure RNA from archival tumor sections
    • How to achieve quantitative measurement of biomarkers and correlation with clinical outcomes in retrospective studies 
    • Q&A opportunities with the experts

    Join us for this scientist-to-scientist presentation to share and discuss how this powerful immunoassay platform can help you meet your research goals faster.


    Show Resources
    Show Resources
    • See more
    Connect with us